President Donald Trump announced new agreements with nine major pharmaceutical companies to lower prescription drug prices for American patients through most-favored-nation pricing. The deals, detailed in a White House fact sheet on December 19, 2025, represent the largest such developments to date in bringing international pricing benchmarks to U.S. consumers.

Under the agreements, participating drugmakers committed to reducing prices on medicines sold through Medicaid and for cash-paying patients. The approach ties U.S. costs to the lowest prices paid in other wealthy nations, addressing long-standing complaints that Americans subsidize global drug development.

Trump has pursued these reductions through direct negotiations since returning to office. Earlier actions included deals with companies such as Eli Lilly and Novo Nordisk on weight-loss medications and the launch of TrumpRx.gov in early 2026, which offers discounted cash prices on select high-cost drugs.

Administration officials described the latest round as historic, noting coverage of a significant portion of the branded drug market. The policy builds on prior executive actions aimed at curbing price increases and promoting domestic manufacturing commitments from the companies involved.

Critics have questioned the immediate impact and noted some list price adjustments in early 2026, but supporters point to the voluntary commitments as concrete progress after years of rising costs. The agreements cover products used by millions of Americans and extend MFN pricing to government programs.

Trump emphasized in related remarks that previous administrations failed to achieve comparable results. The White House continues to highlight additional deals, including one with Regeneron in April 2026, as evidence of sustained momentum.

Patients are expected to see savings through Medicaid access and direct-purchase options as the agreements take effect. The administration has framed these steps as fulfilling campaign promises to lower healthcare expenses without new legislation.